English

Metagenomi, Inc.

EDGAR

MGX Quarterly report (10-Q) · filed 2026-08-10

Annual consolidated revenue for 2025: about USD 25.21M, using the latest reported figures. The previous period, 2024, was about USD 52.3M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

1.25 million USD

2026 Q1 · USD

Exact inputs and evidence

Revenue: 1248000 USD Source

Operating margin

-1,970.11%

2026 Q1 · %

Exact inputs and evidence

Operating Income: -24587000 USD Source
Revenue: 1248000 USD Source

Operating cash flow

-21.2 million USD

2026 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -21175000 USD Source

Free cash flow

-21.2 million USD

2026 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -21175000 USD Source
Capital Expenditure: 25000 USD Source

Cash and cash equivalents: 39 million USD 2026-06-30 Source
Exact value

39028000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 37.8 million shares 2026-06-30 Source
Exact value

37777105 shares

Reported share-count change

0.65% · 244 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

37533136 shares · 2025-06-30· Source
37777105 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

22.3 million USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Revenue: 8513000 USD · 2025-04-01 – 2025-06-30 Source
Revenue: 8659000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 25210000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 21299000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 1248000 USD · 2026-01-01 – 2026-03-31 Source

Net income

-93.5 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -20393000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -87868000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -65340000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -23059000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -27482000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-85.5 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -65346000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -44093000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -88892000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -65346000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -21175000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -40688000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -21175000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

309 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 489000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 415000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 574000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 489000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 25000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 150000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 25000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-85.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -65346000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -44093000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -88892000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -65346000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -21175000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -40688000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -21175000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 489000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 415000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 574000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 489000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 25000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 150000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 25000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-10.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2025-12-31
Operating income: 3 of 11 periods available· newest 2025-12-31
Net income: 3 of 11 periods available· newest 2025-12-31
Operating cash flow: 3 of 11 periods available· newest 2025-12-31
Capital expenditure: 3 of 11 periods available· newest 2025-12-31
Total assets: 3 of 11 periods available· newest 2025-12-31
Total liabilities: 3 of 11 periods available· newest 2025-12-31
Current assets: 3 of 11 periods available· newest 2025-12-31
Current liabilities: 3 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 3 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-51.8%

Prior period

USD 52.3 million

2024-01-01 – 2024-12-31
Current period

USD 25.21 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

25210000 − 52295000 = -27085000 USD

52295000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
25210000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Metagenomi, Inc. · 2025-12-31 Metagenomi, Inc. (edgar:1785279) Year-over-year change in Revenue: -27085000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 25210000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#1928026 Filing: 000119312526093976 Input fundies:Revenue: 52295000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#1929679 Filing: 000119312526093976
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 9.81 million

Prior period

−USD 78.06 million

2024-01-01 – 2024-12-31
Current period

−USD 87.87 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-87868000 − -78058000 = -9810000 USD

-78058000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-87868000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Metagenomi, Inc. · 2025-12-31 Metagenomi, Inc. (edgar:1785279) Year-over-year change in Net income: -9810000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -87868000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2226764 Filing: 000119312526093976 Input fundies:NetIncome: -78058000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2136534 Filing: 000119312526093976
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 20.18 million

Prior period

−USD 109.07 million

2024-01-01 – 2024-12-31
Current period

−USD 88.89 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-88892000 − -109073000 = 20181000 USD

-109073000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-88892000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Metagenomi, Inc. · 2025-12-31 Metagenomi, Inc. (edgar:1785279) Year-over-year change in Operating cash flow: 20181000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -88892000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2322233 Filing: 000119312526093976 Input fundies:OperatingCashFlow: -109073000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2324123 Filing: 000119312526093976
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-81.6%

Prior period

USD 3.11 million

2024-01-01 – 2024-12-31
Current period

USD 574,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

574000 − 3114000 = -2540000 USD

3114000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
574000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Metagenomi, Inc. · 2025-12-31 Metagenomi, Inc. (edgar:1785279) Year-over-year change in Capital expenditure: -2540000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 574000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2328956 Filing: 000119312526093976 Input fundies:CapitalExpenditure: 3114000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2330730 Filing: 000119312526093976
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 25.21 million 100% of revenue
Operating costs Derived USD 121.22 million 481% of revenue
Operating income −USD 96.01 million −381% of revenue
Tax, interest and other Derived −USD 8.15 million −32% of revenue
Net income −USD 87.87 million −349% of revenue

Cash

Operating cash flow −USD 88.89 million −353% of revenue
Capital expenditure USD 574,000 2.3% of revenue
Free cash flow Derived −USD 89.47 million −355% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2023 Operating loss: operating costs were 275% of revenue.
2024 Operating loss: operating costs were 270% of revenue.
2025 Operating loss: operating costs were 481% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2023 2023-01-01 – 2023-12-31	44756000	123248000 Derived	-78492000	-10237000 Derived	-68255000	-101223000 Derived	Source 2023-01-01 – 2023-12-31: 44756000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -78492000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -68255000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -91409000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 9814000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	52295000	141196000 Derived	-88901000	-10843000 Derived	-78058000	-112187000 Derived	Source 2024-01-01 – 2024-12-31: 52295000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -88901000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -78058000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -109073000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 3114000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	25210000	121223000 Derived	-96013000	-8145000 Derived	-87868000	-89466000 Derived	Source 2025-01-01 – 2025-12-31: 25210000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -96013000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -87868000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -88892000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 574000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 25.2M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Revenue	44756000	Revenue: 44756000 Open source
20242024-12-31	Revenue	52295000	Revenue: 52295000 Open source
20252025-12-31	Revenue	25210000	Revenue: 25210000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-51.8% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Year over year	No prior comparable period	Revenue: 44756000 Open source
20242024-12-31	Year over year	16.8%	Revenue: 52295000 Open source Revenue: 44756000 Open source
20252025-12-31	Year over year	-51.8%	Revenue: 25210000 Open source Revenue: 52295000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -380.9% 2025

Net margin -348.5% 2025

Free cash flow margin -354.9% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Operating margin	-175.4%	Operating Income: -78492000 Open source Revenue: 44756000 Open source
20242024-12-31	Operating margin	-170%	Operating Income: -88901000 Open source Revenue: 52295000 Open source
20252025-12-31	Operating margin	-380.9%	Operating Income: -96013000 Open source Revenue: 25210000 Open source
20232023-12-31	Net margin	-152.5%	Net Income: -68255000 Open source Revenue: 44756000 Open source
20242024-12-31	Net margin	-149.3%	Net Income: -78058000 Open source Revenue: 52295000 Open source
20252025-12-31	Net margin	-348.5%	Net Income: -87868000 Open source Revenue: 25210000 Open source
20232023-12-31	Free cash flow margin	-226.2%	Revenue: 44756000 Open source Operating Cash Flow: -91409000 Open source Capital Expenditure: 9814000 Open source
20242024-12-31	Free cash flow margin	-214.5%	Revenue: 52295000 Open source Operating Cash Flow: -109073000 Open source Capital Expenditure: 3114000 Open source
20252025-12-31	Free cash flow margin	-354.9%	Revenue: 25210000 Open source Operating Cash Flow: -88892000 Open source Capital Expenditure: 574000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -88.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Operating cash flow	-91409000	Operating Cash Flow: -91409000 Open source
20242024-12-31	Operating cash flow	-109073000	Operating Cash Flow: -109073000 Open source
20252025-12-31	Operating cash flow	-88892000	Operating Cash Flow: -88892000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -89.5M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Free cash flow	-101223000	Operating Cash Flow: -91409000 Open source Capital Expenditure: 9814000 Open source
20242024-12-31	Free cash flow	-112187000	Operating Cash Flow: -109073000 Open source Capital Expenditure: 3114000 Open source
20252025-12-31	Free cash flow	-89466000	Operating Cash Flow: -88892000 Open source Capital Expenditure: 574000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

28.3% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Liabilities / assets	41%	Total Liabilities: 149668000 Open source Total Assets: 364842000 Open source
20242024-12-31	Liabilities / assets	27.6%	Total Liabilities: 89742000 Open source Total Assets: 324599000 Open source
20252025-12-31	Liabilities / assets	28.3%	Total Liabilities: 62507000 Open source Total Assets: 221103000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.22× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Current assets / current liabilities	4.04×	Current Assets: 278273000 Open source Current Liabilities: 68861000 Open source
20242024-12-31	Current assets / current liabilities	6.91×	Current Assets: 257960000 Open source Current Liabilities: 37309000 Open source
20252025-12-31	Current assets / current liabilities	7.22×	Current Assets: 165538000 Open source Current Liabilities: 22933000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	−USD 68.26 million Exact value Exact value: -68255000 USD 2023-01-01 – 2023-12-31: -68255000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Metagenomi, Inc. · 2023-12-31 Metagenomi, Inc. (edgar:1785279) Net Income: -68255000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -68255000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000095017025040217/mgx-20241231.htm#2586297 Filing: 000095017025040217 The citation records this snapshot. The page link may show a newer release later.	−USD 91.41 million Exact value Exact value: -91409000 USD 2023-01-01 – 2023-12-31: -91409000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Metagenomi, Inc. · 2023-12-31 Metagenomi, Inc. (edgar:1785279) Operating Cash Flow: -91409000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -91409000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000095017025040217/mgx-20241231.htm#2788568 Filing: 000095017025040217 The citation records this snapshot. The page link may show a newer release later.	USD 9.81 million Exact value Exact value: 9814000 USD 2023-01-01 – 2023-12-31: 9814000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Metagenomi, Inc. · 2023-12-31 Metagenomi, Inc. (edgar:1785279) Capital Expenditure: 9814000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9814000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000095017025040217/mgx-20241231.htm#2794724 Filing: 000095017025040217 The citation records this snapshot. The page link may show a newer release later.	−USD 101.22 million Calculation and evidence -91409000 − 9814000 USD Exact free cash flow: -101223000 USD 2023-01-01 – 2023-12-31: -91409000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 9814000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Metagenomi, Inc. · 2023-12-31 Metagenomi, Inc. (edgar:1785279) Free cash flow: -101223000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -91409000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000095017025040217/mgx-20241231.htm#2788568 Filing: 000095017025040217 Input fundies:CapitalExpenditure: 9814000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000095017025040217/mgx-20241231.htm#2794724 Filing: 000095017025040217 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 78.06 million Exact value Exact value: -78058000 USD 2024-01-01 – 2024-12-31: -78058000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Metagenomi, Inc. · 2024-12-31 Metagenomi, Inc. (edgar:1785279) Net Income: -78058000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -78058000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2136534 Filing: 000119312526093976 The citation records this snapshot. The page link may show a newer release later.	−USD 109.07 million Exact value Exact value: -109073000 USD 2024-01-01 – 2024-12-31: -109073000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Metagenomi, Inc. · 2024-12-31 Metagenomi, Inc. (edgar:1785279) Operating Cash Flow: -109073000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -109073000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2324123 Filing: 000119312526093976 The citation records this snapshot. The page link may show a newer release later.	USD 3.11 million Exact value Exact value: 3114000 USD 2024-01-01 – 2024-12-31: 3114000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Metagenomi, Inc. · 2024-12-31 Metagenomi, Inc. (edgar:1785279) Capital Expenditure: 3114000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3114000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2330730 Filing: 000119312526093976 The citation records this snapshot. The page link may show a newer release later.	−USD 112.19 million Calculation and evidence -109073000 − 3114000 USD Exact free cash flow: -112187000 USD 2024-01-01 – 2024-12-31: -109073000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 3114000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Metagenomi, Inc. · 2024-12-31 Metagenomi, Inc. (edgar:1785279) Free cash flow: -112187000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -109073000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2324123 Filing: 000119312526093976 Input fundies:CapitalExpenditure: 3114000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2330730 Filing: 000119312526093976 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 87.87 million Exact value Exact value: -87868000 USD 2025-01-01 – 2025-12-31: -87868000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Metagenomi, Inc. · 2025-12-31 Metagenomi, Inc. (edgar:1785279) Net Income: -87868000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -87868000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2226764 Filing: 000119312526093976 The citation records this snapshot. The page link may show a newer release later.	−USD 88.89 million Exact value Exact value: -88892000 USD 2025-01-01 – 2025-12-31: -88892000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Metagenomi, Inc. · 2025-12-31 Metagenomi, Inc. (edgar:1785279) Operating Cash Flow: -88892000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -88892000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2322233 Filing: 000119312526093976 The citation records this snapshot. The page link may show a newer release later.	USD 574,000 Exact value Exact value: 574000 USD 2025-01-01 – 2025-12-31: 574000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Metagenomi, Inc. · 2025-12-31 Metagenomi, Inc. (edgar:1785279) Capital Expenditure: 574000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 574000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2328956 Filing: 000119312526093976 The citation records this snapshot. The page link may show a newer release later.	−USD 89.47 million Calculation and evidence -88892000 − 574000 USD Exact free cash flow: -89466000 USD 2025-01-01 – 2025-12-31: -88892000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 574000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Metagenomi, Inc. · 2025-12-31 Metagenomi, Inc. (edgar:1785279) Free cash flow: -89466000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:14:59Z Snapshot: c033490695c377064005d826fb400261a053a8be10f488ab578966a744d26367 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1785279?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -88892000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2322233 Filing: 000119312526093976 Input fundies:CapitalExpenditure: 574000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm#2328956 Filing: 000119312526093976 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

17 filings · 884 latest values · 884 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001785279, 1785279, MGX, edgar:1785279

Also known as Metagenomi Technologies, LLC, Metagenomi Therapeutics, Inc., Metagenomi, Inc.

Metagenomi, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation